Diversified Chemicals

Chemours

Chemours released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 1.381 B (forecast USD 1.399 B), actual EPS USD -0.19 (forecast USD 0.01)

Chemours to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 1.398 B, EPS USD 0.05

Chemours Completes $700 Million Bond Issuance to Optimize Debt Structure

Chemours Releases 2025 Annual Report Highlighting 'Path to Prosperity' Strategy Progress

Chemours Plans to Issue $600 Million Senior Notes

Goldman Sachs Raises Chemours Target Price, Chemours Collaborates with Solstice on Efficient Cooling Technology

Chemours Announces Annual Financial Report with Decrease in Net Sales and Net Loss

Chemours released FY2025 annual earnings on February 19 After-Market EST, actual revenue USD 5.808 B (forecast USD 5.801 B), actual EPS USD -2.57 (forecast USD -2.17)

Chemours released FY2025 Q4 earnings on February 19 After-Market EST, actual revenue USD 0 (forecast USD 1.328 B), actual EPS USD 0 (forecast USD -0.035)

Chemours to Release FY2025 Q4 Earnings on February 19 After-Market EST, Forecast Revenue USD 1.328 B, EPS USD -0.035

JPMorgan Downgrades Chemical Company's Target Price to $13

JPMorgan Downgrades Chemours' Target Price to $13

RBC Capital and Truist Financial Analysts Maintain Buy Rating on Chemours

Chemours released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 1.495 B (forecast USD 1.498 B), actual EPS USD 0.3991 (forecast USD 0.23)

Chemours released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 4.478 B, actual EPS USD -2.1708

Chemours to Release Q3 2025 Earnings Report on November 6

Chemours to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 1.498 B, EPS USD 0.23

Osterland Reiterates Hold Rating on Chemours Company

Chemours to Report 2025 Third Quarter Financial Results

Chemours Unveils Sustainable Cooling Solution for Data Centers

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

The Chemours Co. (CC.US) Q4 2024 Earnings Conference Call

Chemours Company reported a Q1 2026 net loss of $29 million despite sales of $1,381 million. The company issued guidance for 2026 net income between $165 million and $225 million, indicating a potential return to profitability. However, unresolved PFAS litigation remains a risk. The stock is currently down 8.4%, with analysts projecting a revenue of $6.6 billion and earnings of $671 million by 2028, suggesting a fair value of $16.33, indicating a 29% downside from its current price.

Simplywall

Chemours (CC) Is Down 8.4% After Issuing 2026 Profit Guidance Amid Q1 Net Loss

A new industry study co-led by The Chemours Company identifies pathways to reduce automotive refrigerant emissions in Europe by approximately 50% between 2030 and 2050. The research indicates that emissions could be cut by over 60% annually by 2050 through coordinated measures across the automotive value chain. Key findings emphasize the importance of collaborative action and circular economy solutions, with no cost impact on consumers due to longer component lifespans and repair savings. The recommendations support both conventional and electric vehicles, promoting sustainability and best practices in the sector.

prnewswire

Solstice Advanced Materials

Solstice Advanced Materials - WI

11:26 ETUn estudio identifica la vía para reducir emisiones acumuladas de refrigerantes de automoción en toda Europa

SOLS

A new industry study co-led by The Chemours Company and Solstice Advanced Materials reveals that automotive refrigerant emissions in Europe could be reduced by over 60% annually by 2050, achieving approximately 50% cumulative emissions reduction between 2030 and 2050. The study emphasizes the importance of collaborative industry action and circular economy solutions, highlighting cost-neutral outcomes for consumers and comparable effectiveness across various vehicle types. The recommendations are ready for rapid adoption, supporting sustainability goals and best practices in the automotive sector.

06:30 ETNew Industry Study, Identifies Path to Cut Cumulative Automotive Refrigerant Emissions Across Europe by ≈50% Between 2030-2050

Chemours Company's stock price target has been raised from $25.2 to $25.6, indicating an 11% potential upside based on the May 8 closing price. The consensus rating remains a 'Buy' from 12 analysts, with 6 Buys, 4 Holds, and 2 Sells. Forecasts for the stock range from $17 to $30 per share.

TradingView

Factset Research

Chemours Company (The) Stock 12‑Month Price Target Raised to $25.6, Implies 11% Upside

The Chemours Company (NYSE:CC) reported a surprise loss of $0.19 per share on revenues of $1.4 billion, leading to a 17% drop in stock price. Analysts have adjusted their forecasts, predicting revenues of $6.02 billion and earnings of $1.21 per share for 2026, down from previous estimates. Despite the earnings downgrade, the price target was raised by 9.8% to $24.89, indicating a positive long-term outlook. Chemours is expected to grow at a rate similar to the industry average, with a projected annual revenue growth of 4.6%.

The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Analyst Duffy Fischer from Goldman Sachs has maintained a Hold rating on Chemours Company, keeping the price target at $18. The decision is based on Chemours’ strong Q1 performance, driven by elevated Freon pricing, but tempered by a cautious outlook for future quarters. Management's Q2 EBITDA guidance is below market expectations, and current earnings strength is linked to temporary HFC pricing benefits. Morgan Stanley also reiterated a Hold rating with a $17 price target.

Tip Ranks

Goldman Sachs

Morgan Stanley

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Chemours: Neutral Stance Maintained as Temporary HFC Tailwinds Offset Cautious Outlook; $18 Price Target Unchanged

Chemours shares are trading lower after the company reported mixed Q1 financial results.

benzinga_article

Chemours(CC.US)